Co-development of therapies and diagnostics has the potential for many clinical benefi ts, such as identification of best responders to therapies, screening for patients most inclined to adverse events, optimization of drug dosing, and more efficient clinical trial processes. Co-developed therapies and diagnostics have been identified by some as potentials to advance personalized medicine. However, there are a number of challenges to realizing the full potential of co-developed products. The business models are challenging and may involve multiple commercial entities, regulatory pathway can be complex, and provider and payers must understand and accept the clinical utility before optimal uptake is realized.

• Identify the potential clinical benefits of co-developed diagnostics and therapeutics
• Explore viable business models for co-developed products, challenges, potential solutions and potential incentives for co-developed products
• Identify the potential benefits and market applications to biotechnology discovery and advances in human health that could be achieved and market applications